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Among women with breast cancer, we compared the relative and absolute rates of subsequent cancers in 1541 women treated with
radiotherapy (RT) to 4570 women not so treated (NRT), using all registered in the Swiss Vaud Cancer Registry in the period
between 1978 and 1998, and followed up to December 2002. Standardised incidence ratios (SIRs) and the corresponding 95%
confidence intervals (CIs) were based on age- and calendar year-specific incidence rates in the Vaud general population. There were
11 lung cancers in RT (SIR¼1.40; 95% CI: 0.70–2.51) and 17 in NRT women (SIR¼0.76; 95% CI: 0.44–1.22), 72 contralateral
breast cancers in RT (SIR¼1.85; 95% CI: 1.45–2.33) and 150 in NRT women (SIR¼1.38; 95% CI: 1.16–1.61), and 90 other
neoplasms in RT (SIR¼1.37; 95% CI: 1.10–1.68) and 224 in NRT women (SIR¼1.05; 95% CI: 0.91–1.19). Overall, there were 173
second neoplasms in RT women (SIR¼1.54, 95% CI: 1.32–1.78) and 391 among NRT women (SIR¼1.13, 95% CI: 1.02–1.25). The
estimates were significantly heterogeneous. After 15 years, 20% of RT cases vs 16% of NRT cases had developed a second neoplasm.
The appreciable excess risk of subsequent neoplasms after RT for breast cancer must be weighed against the approximately 5%
reduction of breast cancer mortality at 15 years after RT.
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Women treated with radiotherapy for breast cancer have an excess
risk of lung, oesophageal, skin cancers and soft tissue sarcomas.
Likewise, cohort studies based on cancer registries in Sweden
(Prochazka et al, 2002), Switzerland (Levi et al, 2003), the UK
(Roychoudhuri et al, 2004) and the US Surveillance, Epidemiology
and End Results (SEER) Programme (Darby et al, 2005) found an
excess lung cancer risk, with overall relative risks (RRs) between
1.3 and 2.0, with a trend towards increasing absolute and RRs with
passing time after breast cancer diagnosis. Data from the Thames
Cancer Registry (Roychoudhuri et al, 2004), the US Surveillance,
Epidemiology and End Results (SEER) Programme (Ahsan and
Neugut, 1998; Zablotska et al, 2005) and the Vaud and Neucha ˆtel
Cancer Registries (Levi et al, 2005) indicated that women who had
received adjuvant radiation therapy (RT) for breast cancer had an
approximately two-fold excess risk of oesophageal cancer 10 years
or more after breast cancer diagnosis. An excess of soft tissue
sarcomas after breast cancer has also been reported (Hartley et al,
1993; Levi et al, 2003); the data are less clear for contralateral
breast cancer (Roychoudhuri et al, 2004).
An overview of 78 randomised trials covering 42000 women
found a significant excess of contralateral breast cancer
(RR¼1.18), lung cancer (RR¼1.61), oesophageal cancer
(RR¼2.06), leukaemias (RR¼1.71), soft tissue sarcomas
(RR¼2.34), as well as all cancers other than breast (RR¼1.20)
(Early Breast Cancer Trialists’ Collaborative Group [EBCTCG],
2005).
We therefore compared the relative and absolute risks of
subsequent cancers among women treated with radiation for
breast cancer (RT) to that of those not treated (NRT), using data
from the Vaud Cancer Registry.
PATIENTS AND METHODS
We used the data set of the Vaud Cancer Registry, which covers
incident cases of malignant neoplasms in the Canton, whose
population, according to the 31 December 2000 census, was
620294 inhabitants (Levi et al, 2001). After exclusion of 21 cases
detected at autopsy, 16 at death, 126 by death certification alone,
573 followed up for o1 month and of synchronous cancers (i.e.
within 1 month after the first primary; n¼25), the present series
comprised 1549 RT and 4570 NRT breast cancer cases, registered
between 1978 and 1998. These 6119 women were followed up to the
end of 2002 for second primary neoplasms, emigration or death,
with a total of 47995 person-years at risk.
Calculation of expected number of cases was based on site-, age-
and calendar year-specific incidence rates of the whole population
of the Canton Vaud, multiplied by the corresponding number of
person-years at risk. The significance of the observed/expected
ratios (standardised incidence ratios, SIRs) and the corresponding
95% confidence intervals (CIs) was based on the Poisson
distribution.
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As shown in Table 1, there were 11 lung cancers in RT (SIR¼1.40)
and 17 in NRT women (SIR¼0.76), 72 contralateral breast cancers
in RT (SIR¼1.85) and 150 in NRT women (SIR¼1.38), and 90
other neoplasms in RT (SIR¼1.37) and 224 in NRT women
(SIR¼1.05). Overall, there were 173 second neoplasms in RT
women (SIR¼1.54, 95% CI: 1.32–1.78) and 391 among NRT
women (SIR¼1.13, 95% CI: 1.02–1.25). The estimates were
significantly heterogeneous. These ratio between RT-treated and
untreated women was 1.84 for lung cancer, 1.34 for breast, 1.30 for
all other neoplasms and 1.36 for all neoplasms combined.
Figure 1 gives the cumulative rates for total cancer incidence in
the two treatment groups up to 15 years after breast cancer
diagnosis. The rates started to diverge around 5 years after breast
cancer diagnosis, when there were 5.5% in RT vs 4.9% in NRT
women; at 10 years, these figures were 11.6% vs 10.3%, and at 15
years 20.2% vs 16.3%. The difference in cumulative incidence of
second neoplasms was significant (w
2
(1)¼4.21, P¼0.04).
DISCUSSION
This study indicates that the risk of lung, breast, and also of all
other neoplasms is increased in women who had received
radiotherapy for breast cancer. The overall excess risk was about
30% for all neoplasms combined, comparable with those recorded
by the EBCTCG (2005). The excess risk became evident in the first
5 years after radiotherapy, and after 15 years 20% of RT vs 16% of
NRT women had developed a second neoplasm.
The present findings are broadly consistent with other popula-
tion-based studies. Thus, the risk of second primary cancer was
evaluated in a cohort of 525527 women with breast cancer
identified from 13 population-based registries in Europe, Canada,
Australia and Singapore, and followed-up between 1943 and 2000
(Mellemkjaer et al, 2006). Among RT women, significant excesses
were observed for cancers of the oesophagus, stomach, lung, soft
tissue sarcomas, thyroid and leukaemias across subsequent strata
of age and calendar years at first primary breast cancer. Similarly,
in three cohorts (1975–1977, 1983–1985, 1991–1993) from the
SEER Programme (Yu et al, 2006), at 8-year follow-up RT women
had a significant excess risk ratio of 1.2 for cancers at all sites, as
well as significant risk ratios for cancer of the breast (1.2), uterine
corpus (1.3) and leukaemias (1.8).
Compared to the lung and breast, most sites probably receive
considerably lower doses of radiation. However, the 30% excess
risk observed for all other neoplasms is still compatible with the
0.97 excess RR per sievert for cohorts of workers occupationally
exposed to low-dose ionising radiation (Cardis et al, 2005).
Although the study is limited by the lack of data on tumour
characteristics including nodal status, and of detailed information
on type and dose of radiotherapy, and is unable to investigate the
risk of the latest radiotherapy techniques, even reduced doses
would still cause appreciable absolute risks of cancer.
The 4% excess absolute risk in total cancer incidence 15 years
after RT has to be weighed against the 5% overall reduction in
breast cancer mortality at 15 years (30.5% in RT vs 35.9% in NRT
women) derived from an overview of 42000 women from 78
randomised trials (EBCTCG, 2005). In the same overview, there
was a 5.3% 15-year gain in total mortality in node-positive RT
women after breast-conserving surgery, and a 4.4% gain in node-
positive ones treated with mastectomy. However, for the overall
data set of node-negative and positive women, the ratio of death
rates for cancers other than breast cancer was 1.12 (EBCTCG,
2005).
In the SEER data set, the risk of radiation-induced heart
disease was several times higher than the risk of radiation-induced
second cancer (Darby et al, 2005). In the EBCTCG (2005), the
excess mortality for circulatory disease was over two-fold higher
than that for lung, oesophageal cancers, leukaemias and soft
tissue sarcomas combined. Radiotherapy techniques have im-
proved in recent years. Consequently, doses to organs other than
the target have been reduced substantially over the last two
decades. This is likely to have a major impact in reducing the
excess mortality from heart disease, but its impact on cancer risk
remains unquantified.
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Figure 1 Cumulative rates for total cancer incidence in 1549 radio-
therapy-treated (RT) and 4570 nonradiotherapy-treated (NRT) women up
to 15 years after breast cancer diagnosis. Vaud, Switzerland.
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